BNBX logo

BNBX
Applied Dna Sciences Inc

22,531
Mkt Cap
$2.73M
Volume
83,411.00
52W High
$8.27
52W Low
$0.371
PE Ratio
-0.01
BNBX Fundamentals
Price
$0.3795
Prev Close
$0.3826
Open
$0.378
50D MA
$0.5789
Beta
0.93
Avg. Volume
2.37M
EPS (Annual)
-$134.23
P/B
0.17
Rev/Employee
$82,189.81
$0.171
Loading...
Loading...
News
all
press releases
BNB Plus Corp. Completes Historic $1.2 Million LineaDNA Order
BNB Plus Corp. (Nasdaq: BNBX) ('BNB Plus' or the 'Company'), today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ('LineaRx'), has successfully completed production of its largest...
News Placeholder
More News
News Placeholder
BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value
BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company"), a Nasdaq-listed digital asset treasury company focused on Binance's BNB token, today announced that its Board of Directors has authorized a formal review of strategic alternatives to maximize shareholder value and also provided an update...
News Placeholder
Anthropic’s ‘Mythos’ Triggers Scramble Among Coinbase, Binance: Report
Large banks and tech organizations have early access to Mythos, while crypto companies still rely on older AI models and internal security technologies.
News Placeholder
BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea IVT Platform
BNB Plus Corp. (Nasdaq: BNBX) ('BNBX' or the 'Company'), announced today that its biopharmaceutical subsidiary, LineaRx, Inc. ('LineaRx'), has been granted a European patent by the European Patent...
News Placeholder
BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA from Genetic Medicine Developers
BNB Plus Corp. (Nasdaq: BNBX) ('BNBX' or the 'Company') today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ('LineaRx'), has received two new orders for LineaDNA from...
News Placeholder
BNB Plus Corp. (BNBX) Appoints James Haft as Independent Board Director
BNB Plus Corp. (Nasdaq: BNBX) ('BNBX' or the 'Company'), today announced the appointment of James Haft as an Independent Director and member of the Boards Nominating Committee, effective as of...
News Placeholder
BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th
BNB Plus Corp. (Nasdaq: BNBX) ('BNBX' or the 'Company'), today announced that Chief Investment Officer Patrick Horsman, CFA and Chairman of the Board Joshua Kruger will present live at the Digital...
News Placeholder
BNB Plus Corp. (BNBX) Receives $1.2M Accelerated LineaDNA Order
BNB Plus Corp. (Nasdaq: BNBX) (BNBX or the Company), today announced that it has received a $1.2M USD order for LineaDNA, representing the largest LineaDNA order in Company history. The order is an...
News Placeholder
BNB Plus Provides BNB Treasury and Operational Updates
BNB Plus Corp. (Nasdaq: BNBX) (BNBX or the Company), today provided a corporate update highlighting its recent strategic treasury growth, expected significant narrowing of losses at its LineaRx, Inc...
News Placeholder
Applied DNA Rebrands as BNB Plus Corp., Elects Josh Kruger as Chairman of the Board
Applied DNA Sciences, Inc. (NASDAQ: BNBX) (the Company) today announced that it will change its name to BNB Plus Corp. (BNB Plus), reflecting the Company's commitment to delivering a yield-optimized...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available